# Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine

> **NCT02173899** · PHASE4 · COMPLETED · sponsor: **Changchun Keygen Biological Products Co., Ltd.** · enrollment: 716 (actual)

## Conditions studied

- Varicella

## Interventions

- **BIOLOGICAL:** varicella-1
- **BIOLOGICAL:** varicella-3
- **BIOLOGICAL:** varicella-5

## Key facts

- **NCT ID:** NCT02173899
- **Lead sponsor:** Changchun Keygen Biological Products Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 716 (ACTUAL)
- **Last updated:** 2014-09-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02173899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02173899, "Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02173899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*